Compare GNK & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | NEO |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 967.7M | 1.0B |
| IPO Year | 2005 | 2008 |
| Metric | GNK | NEO |
|---|---|---|
| Price | $24.72 | $8.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $19.00 | $13.38 |
| AVG Volume (30 Days) | 270.0K | ★ 2.2M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $342,054,000.00 | N/A |
| Revenue This Year | $21.15 | $10.63 |
| Revenue Next Year | $1.41 | $9.73 |
| P/E Ratio | $117.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.66 | $4.72 |
| 52 Week High | $27.25 | $13.74 |
| Indicator | GNK | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 44.32 |
| Support Level | $22.40 | $7.50 |
| Resistance Level | N/A | $8.84 |
| Average True Range (ATR) | 0.90 | 0.55 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 27.45 | 4.29 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.